113 related articles for article (PubMed ID: 3757883)
21. Immunosuppressive activity of ascitic fluid from patients with cancer metastatic to the peritoneum.
Badger AM; Cooperband SR; Merluzzi VJ; Glasgow AH
Cancer Res; 1977 Apr; 37(4):1220-6. PubMed ID: 139204
[TBL] [Abstract][Full Text] [Related]
22. Affinity chromatography separation of tumor associated antigens from ascitic fluid of ovarian cancer patients.
Hill R; Daunter B; Silburn PA; Khoo SK; Mackay EV
Gynecol Oncol; 1983 Jun; 15(3):428-33. PubMed ID: 6407908
[TBL] [Abstract][Full Text] [Related]
23. Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients.
Stallwood Y; Fisher KD; Gallimore PH; Mautner V
Gene Ther; 2000 Apr; 7(8):637-43. PubMed ID: 10800086
[TBL] [Abstract][Full Text] [Related]
24. [Detection of trophoblastic beta 1-glycoprotein in tumor tissue and blood in ovarian neoplasms].
Prokopenko PG; Tatarinov IuS; Borisenko SA; Reshetova TI; Fomina MV
Biull Eksp Biol Med; 1990 Jun; 109(6):573-4. PubMed ID: 2397297
[TBL] [Abstract][Full Text] [Related]
25. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients.
Hess AD; Gall SA; Dawson JR
Cancer Res; 1979 Jul; 39(7 Pt 1):2381-9. PubMed ID: 36225
[No Abstract] [Full Text] [Related]
27. Detection of malignant ovarian neoplasms: a review of the literature. III. Immunological detection and ovarian cancer-associated antigens.
Smith LH; Oi RH
Obstet Gynecol Surv; 1984 Jun; 39(6):346-60. PubMed ID: 6203071
[TBL] [Abstract][Full Text] [Related]
28. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
[TBL] [Abstract][Full Text] [Related]
29. Identification of a human cancer-associated antigen defined with monoclonal antibody.
Bhattacharya M; Chatterjee SK; Barlow JJ
Cancer Res; 1984 Oct; 44(10):4528-34. PubMed ID: 6380708
[TBL] [Abstract][Full Text] [Related]
30. [Immune ascitic fluids in rats to the Sindbis virus].
Pereskokova IG; Blizniuk VV
Vopr Virusol; 1978; (2):244-7. PubMed ID: 78592
[TBL] [Abstract][Full Text] [Related]
31. Lymphocyte stimulation by phytohemagglutinin and tumor cells of malignant effusions.
Robinson E; Sher S; Mekori T
Cancer Res; 1974 Jul; 34(7):1548-51. PubMed ID: 4275697
[No Abstract] [Full Text] [Related]
32. Possibility of immunodiagnosis in ovarian cancer.
Chin Med J (Engl); 1978 May; 4(3):185-90. PubMed ID: 98299
[No Abstract] [Full Text] [Related]
33. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
34. [Detection of gastric cancer associated antigens in ascitic and pleural fluid for ascertaining the nature of the exudate].
Zhang JR; Zhang XY; Chen XT
Zhonghua Nei Ke Za Zhi; 1989 Dec; 28(12):729-30, 768. PubMed ID: 2636090
[TBL] [Abstract][Full Text] [Related]
35. Human kallikrein 8, a novel biomarker for ovarian carcinoma.
Kishi T; Grass L; Soosaipillai A; Scorilas A; Harbeck N; Schmalfeldt B; Dorn J; Mysliwiec M; Schmitt M; Diamandis EP
Cancer Res; 2003 Jun; 63(11):2771-4. PubMed ID: 12782581
[TBL] [Abstract][Full Text] [Related]
36. [Soluble interleukin-2 receptor level in the sera and ascitic fluids in patients with ovarian cancer].
Pu FR; Cheng SW; Zhu D
Zhonghua Fu Chan Ke Za Zhi; 1994 Aug; 29(8):478-80, 511. PubMed ID: 7835120
[TBL] [Abstract][Full Text] [Related]
37. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein.
Garin-Chesa P; Campbell I; Saigo PE; Lewis JL; Old LJ; Rettig WJ
Am J Pathol; 1993 Feb; 142(2):557-67. PubMed ID: 8434649
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
Crombach G; Zippel HH; Würz H
Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies recognizing tumor-associated antigen of human ovarian mucinous cystadenocarcinomas.
Bhattacharya M; Chatterjee SK; Barlow JJ; Fuji H
Cancer Res; 1982 May; 42(5):1650-4. PubMed ID: 6175395
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppressive activity and tissue polypeptide antigen content of human ascitic fluids.
Badger AM; Buehler RJ; Cooperband SR
Cancer Res; 1978 Oct; 38(10):3365-70. PubMed ID: 688226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
